Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
Conclusions Neoadjuvant everolimus given at 5 mg or 10 mg daily for 8 weeks prior to radical prostatectomy did not impact pathologic responses and surgical outcomes of patients with high-risk prostate cancer.Trial registrationNCT00526591.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Investigational New Drugs | Men | Neoadjuvant Therapy | Prostate Cancer | Prostatectomy | Study